The Effect of Amorphous Calcium Carbonate (ACC) Treatment on Function and Welfare in Late-stage Solid Cancer Subjects

NCT03582280 | Terminated Phase 1

• 1 other identifier: AMCS-ONCO-004-1
• Study Type: interventional
• Target: 11
• Locations: 1 country
• Sites: 1

Brief Summary

An exploratory open label study to improve the function and welfare of late-stage solid cancer subjects (with or without lung involvement) who failed or refused anti-cancer treatment by ACC treatment, administered orally and concomitantly by inhalation. The following measures will be evaluated: improvement of pain, performance status, dyspnea measurement (Modified Borg Scale)/ oxygen saturation (if applicable) and overall survival. The subjects' medical charts will be reviewed for their eligibility including the following: medical history, prior cancer treatments, pathologic diagnosis of cancer, and CT/Chest X-ray results. Assessment of prior and concurrent medication use, physician evaluation of patient status, and measurement of Albumin Corrected Serum Calcium level (to be done at baseline and prior to dose escalation, so that results are available prior to the visit) will be performed prior to each dose escalation; in addition, vital signs, ECOG/Karnofsky performance status and VAS pain assessments will be recorded at each visit as well. CT test will be executed during the study period: at baseline, week 12 and week 24 visits in order to assess progression free survival by CT. The tests during the visits will be performed by a physician/nurse. Each subject will receive individual doses of AMOR-powder by escalating doses up to 1,800 mg of ACC powder per day (Amor powder administration will be continuous along the day - each eppendorf every two hours). Patients who will not be able to swallow the powder, will receive similar doses of ACC in tablets. In addition, subject will inhale 1% ACC in 8 ml suspension, for inhalation three times a day. Subject's functionality will be assessed by serially determining ECOG/Karnofsky performance status. Subject's progression free survival will be assessed by CT to evaluate tumor response to treatment.

Conditions

Oncology

Outcome Measures

Primary Outcomes (4)

• Visual Analogue Scale (VAS) score for pain

  Assessing a change in Pain VAS score The scale is between 0-10. 0 is a score for no pain 5 is a score for moderate pain 10 is a score for unbearable pain

  week 0, week 1, week 2, week 3, week 6, week 12, week 18, week 24

• ECOG Performance status (PS)

  Assessing a change in PS Grade 0 - Fully active, able to carry on all pre-disease performance without restriction Grade1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work Grade 2 - Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours Grade 3 - Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours Grade 4 - Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair Grade 5 - Dead

  week 0, week 1, week 2, week 3, week 6, week 12, week 18, week 24

• Oxygen saturation

  Assessing a change in oxygen saturation Normal pulse oximeter readings usually range from 95 to 100 percent. Values under 90 percent are considered low.

  week 0, week 1, week 2, week 3, week 6, week 12, week 18, week 24

• Progression Free Survival

  Assessing a change from baseline in tumor's growth and size by using CT

  week 0, week 12, week 24

Study Arms (1)

Amorous Calcium Carbonate (ACC) - Amor

EXPERIMENTAL

The investigational product will include: 1. Amor powder, each eppendorf contains 200mg Calcium 2. Amor Inhaled Double Pack - 1% ACC in 8 ml suspension

Drug: Amorphous Calcium Carbonate (ACC) - Amor

Interventions

Amorphous Calcium Carbonate (ACC) - Amor DRUG

Amor Powder is composed of Amorphous Calcium Carbonate and is administered oral Amor Inhaled Double Pack is composed of 1% ACC in solution and is administered by inhalation

Amorous Calcium Carbonate (ACC) - Amor

Eligibility Criteria

• Age: 18 Years - 119 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males and females, age 18 years +
• Signed the informed consent
• Late Stage Histologically proven advanced solid tumours for which no standard of care therapy exist or failed or refused anti-cancer treatment
• Subject should not have any illness or condition deemed by the physician to contra-indicate treatment with ACC or may interfere with the assessment of the therapy
• Performance Status: ECOG 0-3/ Karnofsky performance status \>50
• Life Expectancy : at least 2 months
• Hormonal therapy is allowed if needed
• Patient is on conservative treatment for relieving his symptoms
• Subjects within normal range of serum-corrected albumin calcium (between 7.0-10.5 mg/dl)
• Acceptable haematology and biochemistry variables:
• WBC ≥3000/mm3 Absolute Neutrophil count ≥ 1500 /mm3 Platelet Count ≥ 100,000/mm3 Hemoglobin ≥ 9 g/dL Bilirubin ≤ 1.5 x ULN ALT and AST ≤ 2.5 x ULN; for patients with hepatic metastases, ALT and AST ≤ 5 x ULN PT/PTT ≤ 1.5 ULN
• Subjects should have sufficient Vitamin D levels upon study entry, which is defined as 25(OH)D serum level \>20 ng/mL (50 nmol/L) according to a document composed by the Food and Nutrition Board of the Institute of Medicine, USA. If the subject is Vitamin D insufficient or deficient, then a loading dose of Vitamin D3 will be administered during subject's enrollment or during the study as follows:
• If the serum 25(OH)D level is 12-20 ng/mL (30-50 nmol/L) then a loading oral dose of 50,000 IU of Vitamin D3 should be administered twice with 3-5 days in between the doses.
• If the serum 25(OH)D level is ≤ 12 ng/mL (30 nmol/L), then a loading oral dose of 50,000 IU of Vitamin D3 will be administered three times with 3-5 days in between the doses. Serum 25(OH)D levels will be checked 1-2 weeks following the last loading.
• Subjects receiving Denosumab or bisphosphonates are eligible. Denosumab or bisphosphonates can be administered during the study to alleviate bone metastasis pain.

You may not qualify if:

• Concurrent treatment with acute anti-cancer therapy
• Hypercalcemia or previous consistent reporting of hypercalcemia (serum calcium concentration \> 12.0 mg/dL)
• Clinical Significant Cardiovascular Disease
• Known alcohol or drug abuse
• Any psychiatric condition that would prohibit understanding or rendering of Informed Consent
• Brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anti-convulsants for at least 1 month prior to study treatment.
• Nephrolithiasis
• Pregnancy

Sponsors & Collaborators

• Amorphical Ltd.: lead

Study Sites (1)

Hadassah Ein Carem

Jerusalem, Israel

Location

MeSH Terms

Conditions

Neoplasms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 19, 2018
• First Posted: July 10, 2018
• Study Start: July 18, 2018
• Primary Completion: June 30, 2022
• Study Completion: October 31, 2022
• Last Updated: February 28, 2024

Record last verified: 2024-02

Locations

IL (1)